WELLVONE

This brand name is authorized in Australia, Estonia, France, Netherlands, South Africa, Spain, UK.

Active ingredients

The drug WELLVONE contains one active pharmaceutical ingredient (API):

1
UNII Y883P1Z2LT - ATOVAQUONE
 

Atovaquone is a selective and potent inhibitor of the eukaryotic mitochondrial electron transport chain in a number of parasitic protozoa and the parasitic fungus P. jiroveci. The site of action appears to be the cytochrome bc1 complex (complex III).

 
Read more about Atovaquone

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 WELLVONE Oral suspension MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
P01AX06 Atovaquone P Antiparasitic products, insecticides and repellents → P01 Antiprotozoals → P01A Agents against amoebiasis and other protozoal diseases → P01AX Other agents against amoebiasis and other protozoal diseases
Discover more medicines within P01AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
AU Pharmaceutical Benefits Scheme 8300W
EE Ravimiamet 1773110
ES Centro de información online de medicamentos de la AEMPS 63390
FR Base de données publique des médicaments 66955317
GB Medicines & Healthcare Products Regulatory Agency 165909
NL Z-Index G-Standaard 14249642
NL Z-Index G-Standaard, PRK 47147
ZA Health Products Regulatory Authority 31/20.2.6/0033

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.